NCT05652673

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Safe Stop IPI-NIVO Trial: Early Discontinuation of Nivolumab Upon Achieving a (confirmed) Complete or Partial Response in Patients with Irresectable Stage III or Metastatic Melanoma Treated with First-line Ipilimumab-nivolumab

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Erasmus Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Safe Stop IPI-NIVO Trial: Early discontinuation of nivolumab upon achieving a (confirmed) complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab

Conditions

• Melanoma Stage IV
• Melanoma Stage III
• Immunotherapy
• Toxicity, Drug

Interventions

Type	Name	Description
DRUG	nivolumab	Early discontinuation of nivolumab maintenance therapy in patients with irresectable stage III or metastatic melanoma

Timeline

• Start date: 2023-02-01
• Primary completion: 2025-12-01
• Completion: 2029-12-01
• First posted: 2022-12-15
• Last updated: 2025-02-28

Locations

1 site across 1 country: Netherlands